Myriad Genetics Reports Wider Q1 Net Loss, $4.5M Goodwill Impairment, and Proposes New Equity Plans

summarizeSummary

Myriad Genetics reported a significantly wider net loss of $34.1 million for Q1 2026, including a $4.5 million goodwill impairment, and proposed new equity plans that could lead to substantial future dilution.

check_boxKey Events

• Net Loss Widens Significantly

  The company reported a net loss of $34.1 million for Q1 2026, a substantial increase from the $0.1 million net loss in Q1 2025, largely due to the absence of a $29.3 million income tax benefit from the prior year.

• Goodwill Impairment Charge

  Myriad Genetics recognized a $4.5 million goodwill impairment charge attributable to its Women's Health reporting unit, prompted by a sustained decline in its share price and market capitalization.

• Proposed New Equity Incentive Plans

  The Board approved a new 2026 Equity Incentive Plan authorizing up to 8.6 million shares and an amendment to the Employee Stock Purchase Plan for an additional 4.0 million shares, both subject to stockholder approval. If fully issued, these plans represent approximately 13.3% potential dilution based on current outstanding shares.

• Cash Position and Liquidity

  Cash and cash equivalents decreased by $25.2 million in Q1 2026 to $124.4 million. The company used $15.7 million in cash from operating activities during the quarter, but maintains access to $75.0 million in delayed draw term loans.

auto_awesomeAnalysis

Myriad Genetics filed its Q1 2026 10-Q, confirming and elaborating on the financial results previously announced in an 8-K on May 5, 2026. The company reported a significantly wider net loss of $34.1 million for the quarter, compared to a $0.1 million net loss in the prior year, primarily due to the absence of a substantial income tax benefit recognized in Q1 2025. Additionally, the company recognized a $4.5 million goodwill impairment charge related to its Women's Health reporting unit, triggered by a sustained decline in share price and market capitalization. The filing also details proposed new equity incentive plans, including a 2026 Employee, Director and Consultant Equity Incentive Plan authorizing up to 8.6 million shares and an amendment to the Employee Stock Purchase Plan for an additional 4.0 million shares, both subject to stockholder approval. These plans represent significant potential future dilution for existing shareholders. While the company highlighted positive business updates like FDA approval and product launches, the overall financial performance and potential dilution present a negative outlook.